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Abstract. A new rK39 rapid diagnostic dipstick test (DiaMed-IT-Leish) was compared with aspiration and a direct
agglutination test (DAT) for diagnosis of visceral leishmaniasis (VL) in 201 parasitologically confirmed cases, 133
endemic controls, and in 356 clinical suspects in disease-endemic and -epidemic areas in Sudan. The sensitivity of the
rK39 test in parasitologically confirmed VL cases was 90%, whereas the specificity in disease-endemic controls was 99%.
The sensitivity of the DAT was 98%. In clinically suspected cases, the sensitivity of the rK39 test was 81% and the
specificity was 97%. When compared with the diagnostic protocol based on the DAT and aspiration used by Médecins
sans Frontières in epidemic situations, the positive predictive value was 98%, and the negative predictive value was 71%.
This rK39 rapid diagnostic test is suitable for screening as well as diagnosis of VL. Further diagnostic work-up of
dipstick-negative patients with clinically suspected VL is important. The ease and convenience of the dipstick test will
allow decentralization and improved access to care in disease-endemic areas in Sudan.
INTRODUCTION
Clinical diagnosis of visceral leishmaniasis (VL, kala-azar)
is inaccurate. In our experience in Sudan, approximately 50%
of patients meeting the clinical case definition of VL have the
disease; the remainder are diagnosed with other illnesses such
as malaria, typhoid, tuberculosis.
The ultimate confirmation of visceral leishmaniasis is by
demonstration of Leishmania donovani amastigotes in
stained smears from spleen, lymph glands, or bone marrow
aspirates. Splenic aspirates are more sensitive (96%) than
aspirates of bone marrow (70%) or lymph nodes (58%).
1
During the last 15 years, Médecins Sans Frontières (MSF)–
Holland has treated more than 58,000 cases of VL in Sudan
under harsh field conditions. The use of aspirates in these
epidemic and highly endemic settings with large numbers of
patients is limited because of the time and skills required in
preparing and reading the slides. Due to the small but definite
risk of internal bleeding, the use of splenic aspirates in this
setting is further restricted. Bone marrow and lymph node
aspirates are safer, but the material obtained is more dilute
than in a splenic aspirate and thus less sensitive diagnostically.
Moreover, bone marrow sampling is inconvenient and often
painful for the patient. Many patients would be denied life-
saving treatment on the basis of false-negative aspirates if
bone marrow or lymph node aspirations were the only diag-
nostic tool. These characteristics make diagnostic aspiration
of any tissue unsuitable as a routine screening test for VL for
large numbers of patients in a field setting.
Serologic tests have been developed for VL, and the direct
agglutination test (DAT) is used in the Sudan as the first-line
diagnostic tool.
2 DAT titers 1:3,200 have a sensitivity of
94% and a specificity of 72% for active disease.
1 Lower titers
are less specific because of non-specific agglutination and
high prevalence of antibodies to Leishmania because of sub-
clinical and/or past infections with Leishmania species in this
area. Longitudinal studies in a highly endemic village in east-
ern Sudan between 1991 and 1996 show a ratio of clinical to
subclinical infection between 1.2:1 and 2.6:1, in which Leish-
mania antibodies are present without illness.
3,4 When large
numbers of patients are being assessed for kala-azar, e.g.,
during epidemics, high DAT titers (1:6,400) plus a typical
clinical picture may be used as a surrogate method for diag-
nosing kala-azar without aspiration, giving a high predictive
value. Conversely, a low DAT titer (1:400), effectively rules
out kala-azar.
5 Thus, the DAT can be used at a high titer as
a diagnostic test, and at a low titer as a screening test. In the
situation where the patient has a DAT titer >1:400 but
<1:6,400, aspirations are done to confirm a diagnosis of leish-
maniasis. The MSF uses this diagnostic protocol, which re-
duces the number of aspirates by approximately 80%.
6
Although the DAT was specifically developed for epidemic
field situations, it is still difficult to use in remote conditions.
Performance of this test requires a proper laboratory with
skilled technicians to perform correct titer setting, cross-
checking with controls, meticulous implementation, and over-
night incubation. In the field where a laboratory cannot be
established, samples have to be transported to a central labo-
ratory, typically resulting in a delay in starting treatment of
1–2 weeks. Improvements have been made by the introduc-
tion of freeze-dried antigen, which replaces the unstable
aqueous antigen.
7 However, there is an urgent need for a
simpler, faster, non-invasive, but reliable test to screen for
and diagnose kala-azar at the bedside.
Serologic tests have been developed using the cloned anti-
gen rK39 instead of whole Leishmania parasites. The rK39
antigen, which consists of 39 amino acid repeats of a kinesin-
like gene found in L. chagasi, is used in an enzyme-linked
immunosorbent assay (ELISA) format and has shown satis-
factory results in India, Brazil, and the Mediterranean.
8–13
Several recombinant K39 antigen-based dipstick formats have
been developed for rapid field diagnostics by different com-
panies (InBios Inc., Seattle, WA; Arista Biologicals Inc.,
Allentown, PA; and Amrad ICT, Richmond, Victoria, Aus-
tralia). However, the latter two companies no longer produce
these tests. These dipstick formats showed high sensitivity
and specificity in India, Nepal, Bangladesh, and Brazil.
14–20 In
Sudan, previous versions of rK39 antigen-based tests showed
less satisfactory results. An rK39-based ELISA had a sensi-
tivity of 93% in Sudanese VL patients.
21 However, different
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76dipstick formats showed either good specificity but poor sen-
sitivity,
22 or good sensitivity but poor specificity,
23 making
these rapid tests unreliable for diagnosis of kala-azar under
field conditions. The performance of different K39-based
tests in different regions is summarized in Table 1. We evalu-
ated a commercially produced, rK39 antigen-based, rapid di-
agnostic test in highly endemic and epidemic regions in
Sudan.
MATERIALS AND METHODS
Study sites. The evaluation was carried out in three MSF-
Holland kala-azar treatment centers in eastern and southern
Sudan (Um el Kher in Gedaref State, Lankien in Bieh State,
and Bimbim in Latjor State) between November 2003 and
April 2004. These centers are in highly endemic areas, where
regular epidemic outbreaks occur.
24 During the six months of
the study these three centers treated 3,342 new cases of kala-
azar.
Patients. Patients fulfilling the clinical case definition for
suspected kala-azar (fever for >2 weeks with malaria ex-
cluded, wasting, and either splenomegaly or lymphadenopa-
thy) were further evaluated. In this study, we only considered
patients with no history of previous treatment of kala-azar.
All patients were tested by the DAT. A DAT titer 1:6,400
in patients satisfying the clinical case definition was regarded
as diagnostic of VL. Those with borderline DAT titers (1:
800–1:3,200) underwent further parasitologic examination by
aspiration of spleen or lymph nodes. In addition, extra mea-
sures were taken for patients who appeared severely ill to
make a diagnosis as quickly as possible: they underwent as-
piration on the same day as the DAT, and if the initial aspi-
rate was negative, a repeat aspiration was performed the fol-
lowing day with or without a repeat DAT after one week.
Kala-azar was diagnosed after a positive aspirate and/or a
positive DAT (1:6,400). Patients were treated according to
our standard protocol.
6,25 Patients with a negative DAT titer
(1:400) suspected of having VL were evaluated for alterna-
tive diagnoses.
A parasitologically confirmed case of kala-azar was defined
as a patient with positive parasitologic results on either a
spleen or lymph node aspiration smear. A control was defined
as a patient admitted to the MSF health centers for other
reasons than kala-azar, and who had no clinical signs and
symptoms of VL, no history of previous treatment of kala-
azar, and a negative DAT test result. The studies were per-
formed after review and approval from the regional health
authorities. Informed consent was obtained from the study
subjects.
RK39 rapid dipstick test. The rK39 rapid diagnostic test kit
(DiaMed-IT Leish; DiaMed AG, Cressier sur Morat, Swit-
zerland) is composed of a nitrocellulose membrane coated
with a line of recombinant antigen K39 across the strip. An-
tibodies to Leishmania present in a blood sample react with
K39 antigen, and their presence is shown by mouse anti-
human antibody conjugated to an indicator. A finger prick
sample (20 L) of blood is added to a well and mixed with a
drop of buffer. A DiaMed-IT Leish test strip is placed verti-
cally in the well, and the diluted blood rises up the nitrocel-
lulose strip. After the blood is completely wicked up, the strip
is transferred to the next well, which contains a few drops of
wash buffer, and allowed to clear. The entire process takes
approximately 20 minutes and results are read visually. A
control line at the top of the strip verifies that the test strip is
functional. If this is the only line that appears, then the test
result is considered negative; two lines are positive for VL.
Parasitologic diagnosis. Parasitologic confirmation of VL
was established by microscopic demonstration of Leishmania
amastigotes in Giemsa-stained smears from either spleen or
lymph node aspirates. A parasite density score was deter-
mined using a scale ranging from 0 (no parasites per 1,000
oil-immersion fields) to +6 (>100 parasites per field).
26
Direct agglutination test. The DAT was performed as pre-
viously described using freeze-dried antigen (L. donovani
TABLE 1
Overview of rK39 antigen-based test results for visceral leishmaniasis (VL)*
Location/Name Year Country Format Company Total sample VL cases Sensitivity (%) Specificity (%)
South Asia
Sundar S 1998 India Dipstick Arista 344 127 100 98
Bern C 2000 Nepal Dipstick Inbios 127 14 100 100
Qu JQ 2000 China Dipstick Inbios 13 13 100
Singh S 2002 India Dipstick Inbios 308 228 100 100
Sarker CB 2003 Bangladesh Dipstick Amrad 180 60 97 98
Chappuis F 2003 Nepal Dipstick Inbios 184 139 97 71
Boelaert M 2004 Nepal Dipstick Inbios 310 87 93
Latin America
Delgado O 2001 Venezuela Dipstick Inbios 117 41 88 100
Braz RF 2002 Brazil ELISA Inbios 208 120 93 99
Carvalho SG 2003 Brazil Dipstick Inbios 188 128 90 100
Mediterranean
Ozensoy S 1998 Turkey ELISA 71 24 96 94
Maalej IA 2003 Tunisia ELISA Inbios 146 38 100 97
Sudan
Zijlstra EE 1998 Sudan ELISA Inbios 15 15 93
Zijlstra EE 2001 Sudan Dipstick Arista 116 55 67 97
Veeken H 2003 Sudan Dipstick Amrad 77 50 92 59
MSF unpublished 1999 Sudan Dipstick Inbios 91 60 67 87
Present study 2004 Sudan Dipstick DiaMed 338 201 90 99
* ELISA  enzyme-linked immunosorbent assay.
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Royal Tropical Institute (Amsterdam, The Netherlands).
7
Samples with known DAT titers were included as standards.
The titer of the sample is expressed as the highest dilution at
which agglutination is still visible.
Statistical analysis. Data entry and statistical analysis was
done using Epi-Info (Centers for Disease Control and Pre-
vention, Atlanta, GA). Proportions were compared using the
chi-square test with Yates’ correction, or Fisher’s exact test,
where appropriate. Sensitivity, specificity, and positive pre-
dictive values were estimated with exact binomial 95% con-
fidence intervals (CIs).
RESULTS
Performance of rK39 dipstick in confirmed VL cases and
endemic controls. A total of 201 parasitologically confirmed
VL cases (152 in Um-el-Kher and 49 in Lankien; 157 by
lymph node aspirate and 44 by splenic aspirate) were evalu-
ated with the dipstick; 180 of 201 were positive. Thus, the
sensitivity of the dipstick in these parasitologically confirmed
cases was 89.6% (95% CI  84.5–93.4%). No significant dif-
ference observed in sensitivity between the Um-el-Kher and
Lankien sites (91.4% versus 83.7%; P  0.20).
Among the 201 parasitologically confirmed cases, 197 had a
positive DAT test result (titer  1:6,400). Thus, the sensitivity
of the DAT at high titer was 98.0% (95% CI  95.0–99.5%),
which was significantly higher than the rK39 dipstick (P 
0.001). Using a titer > 1:400, the sensitivity of the DAT was
99.0% (199 of 201).
A total of 133 endemic controls were recruited. Only one
control had a positive rK39 dipstick test result, but this con-
trol also had a negative lymph node aspirate and a negative
DAT result. Thus, the specificity was 99.2% (95% CI  95.9–
100%) (Table 2).
All cases and controls at the Um-el-Kher site were system-
atically checked for malaria by blood smear. Of the confirmed
cases, 21.7% had malaria parasitemias. Of the endemic con-
trols, 29.0% had malaria parasitemias (P  0.34). Malaria
prevalence was identical in persons with true-positive and
false-positive rK39 dipstick results (P  1.00).
Performance of rK39 dipstick in suspected VL cases. A to-
tal of 356 consecutive, unselected clinically suspected kala-
azar cases in Lankien and Latjor sites were prospectively
evaluated. Fifteen suspected cases with borderline positive
DAT results (titers  1:800–1:3,200) were excluded from the
analysis because their diagnosis remained uncertain; no aspi-
ration could be done under prevailing field conditions.
Among the remaining 341 individuals the rK39 dipstick was
compared with diagnosis by high-titer DAT, positive aspirate,
or both. The dipstick had a sensitivity of 80.7% (95% CI 
75.2–85.6%), a specificity of 97.3% (95% CI  92.4–99.4%),
a positive predictive value of 98.4% (95% CI  95.4–99.7%),
and a negative predictive value of 71.4% (95% CI  63.6–
78.4%) (Table 3).
DISCUSSION
When evaluating a new test, it is difficult to be sure whether
disagreements arise from inaccuracy in the new test or in
existing tests. The high sensitivity (90%) of the DiaMed-IT
Leish rK39 rapid diagnostic test in parasitologically con-
firmed cases means that it is a good screening test for kala-
azar in the Sudan, although is significantly less sensitive than
the DAT (sensitivity  98–100% in this study). Sensitivity is
not influenced by presence of malaria. The lower sensitivity
of the dipstick test when compared with the standard MSF
diagnostic protocol (based on the DAT and aspiration) than
if compared with parasitologically confirmed VL cases may
be attributable to the specificity of the DAT test. Several
studies in Sudanese kala-azar have shown specificity esti-
mates of the DAT between 72% and 99%, which may result
in significant overdiagnosis among clinically suspected pa-
tients.
5,22,27–29
The rK39 dipstick has high specificity (99% in endemic
controls and 97% in clinically suspected patients), making
overdiagnosis of kala-azar unlikely, despite the high back-
ground prevalence of antibodies against L. donovani in this
region.
3,4 The lower specificity found in aspirate-negative
clinical suspects may be attributable to the low sensitivity of
lymph node aspirates,
1 which results in possible false-negative
aspirate results.
Our standard diagnostic work-up has been based on mi-
croscopy and the DAT, both of which require laboratory ser-
vices with well-trained laboratory technicians. In situations
where field laboratories cannot be established (for reasons of
security or capacity), transportation of filter papers contain-
ing blood samples for DAT testing from peripheral units to
centralized laboratories often results in an unacceptable treat-
ment delay. Simple, rapid, and cheap serologic dipstick tests
are therefore urgently required. The DiaMed-IT Leish can be
used with whole capillary blood, does not require a cold
chain, and can be stored for least one year under the high field
temperatures in the Sudan (25–40°C). Community health
workers in peripheral health units can easily perform the test.
A positive dipstick test result in a clinically suspected case of
kala-azar can be considered confirmation of the disease with
a high level of certainty, and the patient can be treated im-
mediately. Especially in southern Sudan, where access to
kala-azar care is very poor, kala-azar patients often come for
treatment after a prolonged symptomatic period in a critical
TABLE 2
Results of the rK39 dipstick test in 201 confirmed visceral leishma-
niasis cases and 133 endemic controls
Dipstick Cases Controls
Positive 180 1
Negative 21 132
Total 201 133
TABLE 3
Results of the rK39 dipstick test compared with Me ´decins Sans Fron-
tie `res diagnostic protocol (DAT  1:6,400 or aspirate positive) in
341 clinical suspects*
Dipstick
DAT positive ( 1:6,400)
and/or
positive aspirate
DAT negative ( 1:400) or
DAT borderline with
negative aspirate Total
Positive 184 3 187
Negative 44 110 154
Total 228 113 341
* DAT  direct agglutination test.
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30 Decentralized diagnosis will allow active case-
finding, reduce delays, and improve chances of survival. Be-
cause the sensitivity of the rK39 dipstick is 90%, 10% of
kala-azar patients (dipstick false-negative results) may die
without treatment if the disease is not otherwise confirmed.
Therefore, a backup protocol (using the DAT and/or aspira-
tion) remains essential for clinically suspect VL cases with a
negative rK39 dipstick test results. Therefore, rapid parasite
antigen tests or Leishmania DNA/RNA detection tests might
be an important improvement in serodiagnosis. This is par-
ticularly important in view of increasing human immunodefi-
ciency virus/VL co-infection rates in eastern Africa, which are
expected to reduce the validity of serologic tests.
11
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